BioSET

BioSurface Engineering Technologies, Inc., also known as BioSET, engages in developing proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair. The company focuses on developing devices for orthobiologics applications. Its products include AMPLEX, an implantable combination device of the B2A peptide and a synthetic ceramic scaffold for use as a surgical bone graft implant for lumbar degenerative disc disease, as well as for use in spine, cervical spine, and foot and ankle fusion surgeries. The company also develops products for sports medicine applications based on its F2A peptide; and peptide signaling molecules and various scaffold biomaterials for use in musculoskeletal applications, including trauma, fracture repair, and other soft tissue treatments. BioSurface Engineering Technologies, Inc. was founded in 2001 and is based in Rockville, Maryland.

BioSET headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $1.8B in funding across 80 round(s). With a team of 11-50 employees, BioSET is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - BioSET, raised $6.8M. Discover more about their projects, partnerships, and impact on our platform.